Read the blog
The U.S. FDA issued Development and Licensure of Vaccines to Prevent COVID-19: Guidance for Industry to provide its perspective on (and recommendations) for the CMC (chemistry, manufacturing, and control), nonclinical, and clinical aspects related to such vaccines.
Bring your talents and forward-thinking approach to Altasciences and help us develop medicines for those who need them, faster. We have a number of opportunities for you to explore.
Webinar
As you work towards a successful New Drug Application (NDA) submission, there are many considerations that must be taken into account, specifically for CNS-active drugs.
Safety assessments for both small and large molecules
Clinical pharmacology trials from first-in-human to end of Phase II
From formulation development, phase I through commercial manufacturing, and ICH stability testing
As part of our full service offering or as standalone solutions
Comprehensive CRO services to support clinical and preclinical studies
 |
||||||||||
| »ACCESS FULL NEWSLETTER | ||||||||||
|
Our deep expertise and capabilities in a broad range of therapeutic areas encompasses preclinical and early clinical studies for both small molecules and biologics. We can manage your entire program, as well as provide comprehensive support research services and bioanalytical expertise.
Please see Therapeutic Areas for a fuller discussion of our capabilities and expertise.
Working as a flexible, attentive extension of your team, we offer all you need to move your molecule forward.
